Pegfilgrastim: A New Therapy to Prevent Neutropenic Fever
- 31 October 2002
- journal article
- Published by Elsevier in Journal of the American Pharmaceutical Association
- Vol. 42 (5), 806-808
- https://doi.org/10.1331/108658002764653595
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with CancerClinical Infectious Diseases, 2002
- Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast CancerJournal of Clinical Oncology, 2002
- Filgrastim (r-metHuG-CSF) in the 21st Century: SD/01Acta Haematologica, 2001
- 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice GuidelinesJournal of Clinical Oncology, 2000
- Randomized, Dose-Escalation Study of SD/01 Compared With Daily Filgrastim in Patients Receiving ChemotherapyJournal of Clinical Oncology, 2000
- Filgrastim (r-metHuG-CSF): the first 10 yearsBlood, 1996
- Decision Analysis of Hematopoietic Growth Factor Use in Patients Receiving Cancer ChemotherapyJNCI Journal of the National Cancer Institute, 1993